Results 181 to 190 of about 3,819 (202)

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

International Journal of Stroke, 2020
Pawel Kermer, Christoph C Eschenfelder, Hans-Christoph Diener   +2 more
exaly  

Dabigatran etexilate/idarucizumab

Reactions Weekly, 2019
  +4 more sources

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

Lancet, The, 2015
Stephan Glund
exaly  

Idarucizumab for Dabigatran Reversal Guideline

Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 2016
David P, Reardon, Kent, Owusu
openaire   +2 more sources

Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding

Circulation, 2019
Sake J Van Der Wall, Stephan Glund, Frederikus A Klok   +2 more
exaly  

Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes

Thrombosis Research, 2023
exaly  

Dabigatran etexilate/idarucizumab

Reactions Weekly, 2021
openaire   +1 more source

Dabigatran etexilate/idarucizumab

Reactions Weekly
  +5 more sources

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection

International Journal of Stroke, 2017
Pawel Kermer, Hans-Christoph Diener, Katharina Althaus   +2 more
exaly  

Dabigatran-etexilate/idarucizumab

Reactions Weekly, 2023
openaire   +1 more source